Anatara Lifesciences Limited Stock Market Press Releases and Company Profile
Quarterly Cashflow
Quarterly Cashflow

Brisbane, Jan 15, 2020 AEST (ABN Newswire) - Anatara Lifesciences Ltd (googlechartASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m (30th September 2019: $4.45m). On 31st December 2019, the Company had cash at bank of $3,801,117 and $500,000 in term deposits. Expenditure during the quarter was lower than forecast due to timing of payments for R&D expenditure.

Anatara made two notable announcements during the quarter; reporting the achievement of key milestones for its GaRP dietary supplement development program: (1) additional successful preclinical data, including observing an adjuvant effect and potential dose-sparing properties when combined with a commonly used class of disease modifying medication; (2) finalisation of the draft clinical trial protocol in irritable bowel syndrome (IBS).

To view the release, please visit:
https://abnnewswire.net/lnk/VTV619SM


About Anatara Lifesciences Limited

Anatara Lifesciences ASX ANRAnatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. 

 

https://twitter.com/anataraanr https://www.facebook.com/profile.php?id=61550997392627 https://www.linkedin.com/company/anatara-lifesciences-ltd abnnewswire.com 


Contact

Investor and Media inquiries

Steven Lydeamore
Chief Executive Officer
Anatara Lifesciences Ltd
T: +61-438-027-172
E: slydeamore@anatara.com

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: +61-437-211-200
E: smacleman@anatara.com



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 11) (Last 30 Days: 35) (Since Published: 6436)